Crinetics Pharmaceuticals, Inc.
CRNX
Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is Paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist that has completed phase III clinical trial for the treatment of acromegaly, as weā¦ read more
Healthcare
Biotechnology
7 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$46.03
Price+2.95%
$1.32
1Y
Price
Market Cap
$4.368b
Mid
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-90265.0%
EBITDA Margin-90972.7%
Net Profit Margin-78028.7%
Free Cash Flow MarginRevenue
$1.535m
+47.7%
1y CAGR-13.9%
3y CAGR+74.4%
5y CAGREarnings
-$423.097m
-41.8%
1y CAGR-37.2%
3y CAGR-41.0%
5y CAGREPS
-$4.53
-22.8%
1y CAGR-13.3%
3y CAGR-13.1%
5y CAGRBook Value
$1.072b
$1.196b
Assets$123.862m
Liabilities$49.144m
DebtDebt to Assets
4.1%
-0.1x
Debt to EBITDAFree Cash Flow
-$356.028m
-54.9%
1y CAGR-45.2%
3y CAGR-41.7%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company